{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:00:12Z","timestamp":1785859212135,"version":"3.56.0"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T00:00:00Z","timestamp":1466640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0157961","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T13:54:15Z","timestamp":1466690055000},"page":"e0157961","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials"],"prefix":"10.1371","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5868-9769","authenticated-orcid":true,"given":"Emilia","family":"Quattrocchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald F.","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Kurrasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,6,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes","volume":"40","author":"JC Edwards","year":"2001","journal-title":"Rheumatology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","article-title":"Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion","volume":"61","author":"MJ Leandro","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"JC Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/rheumatology\/kel393","article-title":"Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs","volume":"46","author":"C Popa","year":"2007","journal-title":"Rheumatology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterisation of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin\u2019s lymphomas","volume":"104","author":"JL Teeling","year":"2004","journal-title":"Blood"},{"key":"ref6","first-page":"1733","article-title":"Handbook of Therapeutic Antibodies","author":"MA Lindorfer","year":"2014"},{"key":"ref7","first-page":"1206","article-title":"Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies","volume":"9","author":"G Hutas","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/art.23732","article-title":"Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I\/II randomized, blinded, placebo controlled, dose-ranging study","volume":"58","author":"MC Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2008-07-168146","article-title":"Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody","volume":"113","author":"DM Goldenberg","year":"2009","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"E Mossner","year":"2010","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4049\/jimmunol.0900632","article-title":"Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX","volume":"183","author":"AW Pawluczkowycz","year":"2009","journal-title":"J Immunol"},{"key":"ref12","unstructured":"Arzerra (ofatumumab) prescribing information. April 2014. [internet] Available: https:\/\/www.gsksource.com\/gskprm\/htdocs\/documents\/ARZERRA.PDF<\/ext-link>"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1002\/art.27524","article-title":"Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs. Results of a randomized, double-blind, placebo-controlled, phase I\/II study","volume":"62","author":"M \u00d8stergaard","year":"2010","journal-title":"Arthritis Rheum"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1136\/ard.2011.151522","article-title":"Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial","volume":"70","author":"PC Taylor","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose ranging trial","volume":"54","author":"P Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3899\/jrheum.121118","article-title":"Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I\/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics","volume":"40","author":"R Kurrasch","year":"2013","journal-title":"J Rheumatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"FC Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","article-title":"Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies","volume":"64","author":"ES Molloy","year":"2012","journal-title":"Arthritis Rheum"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"RF van Vollenhoven","year":"2010","journal-title":"J Rheumatol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"RF van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"ref21","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"JE Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e87379","DOI":"10.1371\/journal.pone.0087379","article-title":"Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program","volume":"9","author":"P Emery","year":"2014","journal-title":"PLoS ONE"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3899\/jrheum.110994","article-title":"Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo controlled double-blind parallel-group study","volume":"39","author":"M Harigai","year":"2012","journal-title":"J. Rheumatol"},{"key":"ref24","year":"2010"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"SB Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00296-009-1202-2","article-title":"Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis","volume":"31","author":"A Pyrpasopoulou","year":"2011","journal-title":"Rheumatol Int"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jbspin.2011.07.003","article-title":"Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis","volume":"79","author":"E Ghr\u00e9nassia","year":"2012","journal-title":"Joint Bone Spine"},{"key":"ref28","first-page":"91","article-title":"Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab","volume":"17","author":"E Gigi","year":"2013","journal-title":"Hippokratia"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"E Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","article-title":"Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological na\u00efve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab\u2019s Effi cacy in MTX iNadequate rEsponders (SERENE))","volume":"69","author":"P Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"MH Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.21650","article-title":"Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment","volume":"54","author":"G Cambridge","year":"2005","journal-title":"Arthritis Rheum"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0157961","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T09:19:22Z","timestamp":1540027162000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0157961"}},"subtitle":[],"editor":[{"given":"Arvind","family":"Chopra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,6,23]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,6,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0157961","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,23]]}}}